Plasma MicroRNA Panel ID’d for Diagnosing Hepatocellular Cancer

StephenW

http://www.doctorslounge.com/index.php/news/pb/24779
Plasma MicroRNA Panel ID’d for Diagnosing Hepatocellular CancerLast Updated: November 22, 2011.
Hepatitis B virus-related hepatocellular carcinoma can be diagnosed with high accuracy using a microRNA panel, according to a study published online Nov. 21 in the Journal of Clinical Oncology.
TUESDAY, Nov. 22 (HealthDay News) -- Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) can be diagnosed with high accuracy using a microRNA panel, according to a study published online Nov. 21 in the Journal of Clinical Oncology.
Jian Zhou, M.D., Ph.D., from Fudan University in Shanghai, China, and colleagues sought to identify plasma microRNAs for diagnosing HBV-related HCC. A total of 934 participants, including healthy individuals, and those with chronic hepatitis B, cirrhosis, and HBV-related HCC, were selected between August 2008 and June 2010. Initially, 723 microRNAs in 137 plasma samples were screened using a microarray to diagnose HCC. The expression of selected microRNAs was subsequently evaluated using a quantitative reverse-transcriptase polymerase chain reaction assay. A training cohort comprising 407 individuals was used to create a logistic regression model, which was then validated using an independent cohort of 390 individuals. The diagnostic accuracy was assessed using the area under the receiver operating characteristic curve (AUC).
The investigators found that a microRNA panel, including miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, and miR-801, provided high accuracy for diagnosis of HCC, with an AUC of 0.864 and 0.888 for the training and validation data sets, respectively. The diagnostic performance persisted irrespective of disease status. The microRNA panel was able to differentiate between HCC and samples from healthy individuals (AUC, 0.941), chronic hepatitis B (AUC, 0.842), and cirrhosis (AUC, 0.884).
"We found a plasma microRNA panel that has considerable clinical value in diagnosing early-stage HCC," the authors write.

StephenW

等离子体微RNA对肝癌的诊断小组ID'd


    小组区分慢性乙型肝炎，肝硬化，肝癌和健康样本



乙肝病毒相关性肝细胞癌可以诊断使用的microRNA面板的准确性高，根据11月21日在线发表在临床肿瘤学杂志的一项研究。

周二，11月22日（健康新闻） - B型肝炎病毒（HBV）相关肝细胞癌（HCC）可以诊断使用的microRNA面板与高准确性，根据11月21日在线发表在临床肿瘤学杂志的一项研究。

周健，医学博士，在中国上海复旦大学，和他的同事试图确定诊断HBV相关HCC的血浆中的microRNA。共有934人参加，包括健康人，慢性乙型肝炎，肝硬化，HBV相关HCC，2008年8月和2010年6月之间选择。最初，723中的137个血浆样品的microRNA进行了筛选，利用基因芯片诊断肝癌。选定的小分子RNA的表达，其后用定量逆转录聚合酶链反应检测评估。由407个人组成的一个训练队列被用来创建一个Logistic回归模型，这是当时使用390个人的独立队列验证。使用受试者工作特征曲线（AUC）下面积诊断的准确性进行了评估。

研究者发现的microRNA面板，包括miR - 122，miR - 192的中，miR - 21，miR - 223的MIR - 26A，MIR - 27A和miR - 801，对肝癌的诊断提供了高精确度的AUC， 0.864和0.888的培训和验证数据集，分别。坚持不论疾病状态的诊断性能。的microRNA面板能够区分肝癌和样品之间的健康人（AU​​C，0.941），慢性乙型肝炎（AUC，0.842），肝硬化（AUC，0.884）。

“我们发现了等离子的microRNA面板，在诊断早期肝癌的临床应用价值，”作者写道。